利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤的可行性研究  

Feasibility Study of Rituximab-assisted CHOP Regimen in the Treatment of B-cell Non-Hodgkin's Lymphoma

作　　者：张晓芸 ZHANG Xiao-yun(Department of Hematology,Second People's Hospital, Qujing,Yunnan Province,655000 China)

机构地区：[1]云南省曲靖市第二人民医院血液肿瘤科,云南曲靖655000

出　　处：《系统医学》2019年第7期123-125,共3页Systems Medicine

摘　　要：目的分析利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤的可行性。方法以2015年1月—2017年10月进入该院治疗的52例B细胞型非霍奇金淋巴瘤患者为调查目标,结合其个人意愿划入联合组与常规组(n=26)。常规组应用CHOP方案治疗,联合组在此基础上应用利妥昔单抗治疗,对比两组患者的整体有效率、不良反应发生率及生存情况。结果联合组患者整体治疗有效率为96.15%,显著高于常规组患者整体治疗有效率76.92%,数据对比差异有统计学意义(χ~2=7.17,P=0.017<0.05)。治疗期间常规组患者出现5例不良反应,联合组患者出现4例不良反应,组间数据比较无统计学意义(χ~2=2.01,P>0.05)。随访12个月,联合组死亡2例,常规组死亡6例,差异有统计学意义(χ~2=7.41,P<0.05)。结论利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤,有助于提升患者的临床治疗有效率,且联合用药方式下不会显著增加患者不良反应发生率。Objective To analyze the feasibility of rituximab-assisted CHOP regimen in the treatment of B-cell nonHodgkin’s lymphoma. Methods A total of 52 patients with B-cell non-Hodgkin’s lymphoma who entered the hospital from January 2015 to October 2017 were enrolled in the study. They were included in the combination group and the routine group(n=26). The conventional group was treated with CHOP regimen. The combination group was treated with rituximab on the basis of this, and the overall effectiveness, adverse reaction rate and survival of the two groups were compared. Results The overall treatment efficiency of the combined group was 96.15%, which was significantly higher than that of the conventional group. The overall treatment efficiency was 76.92%. There was a statistical difference in the data comparison(χ^2=7.17, P=0.017<0.05). There were 5 adverse reactions in the routine group and 4 adverse reactions in the combined group. There was no statistically significant difference between the two groups(χ^2=2.01, P>0.05).During the follow-up of 12 months, 2 patients died in the combined group and 6 patients died in the conventional group. The difference was statistically significant(χ^2=7.41, P<0.05). Conclusion Rituximab-assisted CHOP regimen in the treatment of B-cell non-Hodgkin’s lymphoma may help to improve the clinical efficacy of patients, and the combination of drugs will not significantly increase the incidence of adverse reactions.

关 键 词：利妥昔单抗 CHOP方案治疗 B细胞型非霍奇金淋巴瘤 

分 类 号：R73[医药卫生—肿瘤]